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Abstract
We hypothesize that the primary mechanism for removal of glutamate from the extracellular space is altered after
traumatic brain injury (TBI). To evaluate this hypothesis, we initiated TBI in adult male rats using a 2.0 atm lateral fluid
percussion injury (LFPI) model. In the ipsilateral cortex and hippocampus, we found no differences in expression of the
primary glutamate transporter in the brain (GLT-1) 24 h after TBI. In contrast, we found a decrease in glutamate uptake in
the cortex, but not the hippocampus, 24 h after injury. Because glutamate uptake is potently regulated by protein kinases,
we assessed global serine-threonine protein kinase activity using a kinome array platform. Twenty-five kinome array
peptide substrates were differentially phoshorylated between LFPI and controls in the cortex, whereas 19 peptide sub-
strates were differentially phosphorylated in the hippocampus (fold change ‡ – 1.15). We identified several kinases as
likely to be involved in acute TBI, including protein kinase B (Akt) and protein kinase C (PKC), which are well-
characterized modulators of GLT-1. Exploratory studies using an inhibitor of Akt suggest selective activation of kinases in
LFPI versus controls. Ingenuity pathway analyses of implicated kinases from our network model found apoptosis and cell
death pathways as top functions in acute LFPI. Taken together, our data suggest diminished activity of glutamate
transporters in the prefrontal cortex, with no changes in protein expression of the primary glutamate transporter GLT-1,
and global alterations in signaling networks that include serine-threonine kinases that are known modulators of glutamate
transport activity.
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Introduction
Traumatic brain injury (TBI) is a persistent major healthproblem in the United States, with an annual incidence rate of
*200 per 100,000 people and *10,000,000 hospitalizations or
deaths per year.1 TBI can lead to long-lasting cognitive and be-
havioral impairments, and is the leading cause of death resulting
from injury in individuals <45 years of age.2 Although the trauma
itself is typically a one-time event, TBI can be understood as an
ongoing pathological process consisting of two distinct phases. The
initial stage, primary injury, is a direct result of the mechanical
forces applied to the brain that induce hemorrhage, contusion, and
axonal shearing. The second stage, secondary injury, is character-
ized as a prolonged, diffuse pathophysiological sequence of events,
which may include release of excitatory neurotransmitters, free
radical production, mitochondrial damage, changes in protein ex-
pression, and cell death.3
The metabolic and cellular derangements that are characteristic
of the secondary injury phase are largely initiated by massive and
indiscriminant release of glutamate into the extracellular space.4
Although glutamate is the primary excitatory neurotransmitter in
the mammalian central nervous system, its interstitial concentra-
tions must be actively maintained, as it can be toxic to neurons even
at low extracellular concentrations.5 Various microdialysis studies
demonstrate that within minutes of a person’s sustaining a TBI,
extracellular glutamate levels rise sharply in a force-dependent
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manner,6 with some reports indicating a ninefold increase in ex-
tracellular glutamate levels following a severe lateral fluid per-
cussion injury (LFPI).7 These excitotoxic levels of extracellular
glutamate arise from a number of factors. The mechanical force
associated with the primary injury can result in direct disruption of
the cell’s plasma membrane and lead to indiscriminate electrical
discharge, either of which may precipitate the release of intracel-
lular ions and glutamate into the extracellular space.4,8 The ionic
imbalance and widespread cellular derangement associated with
the secondary injury phase may result in astrocyte cell death,
caspase-mediated degradation of glutamate transporters, changes
in key intracellular signaling pathways, and reversal of sodium-
dependent glutamate transport; all of which have been implicated
in furthering the pathological sequelae associated with TBI.8–11
Extracellular concentrations of glutamate are maintained by a
family of sodium- dependent glutamate transporters, which are
selectively expressed throughout the mammalian brain on both
neurons and glia.12 The glutamate and aspartate transporter
(GLAST) and the glutamate transporter-1 (GLT-1) are expressed
primarily in astrocytes, whereas the remaining transporters reside
primarily on neurons.13 Of the astrocyte transporters, GLT-1 is
responsible for *90% of the clearance of glutamate from the
synapse in most brain regions.14 The astrocytic glutamate trans-
porters are crucial for the proper maintenance of extracellular
glutamate levels, and alterations in glutamate transporter expres-
sion leads to abnormalities of neuronal function and viability.15–19
Glutamate transporter function may be compromised following
TBI. 20 For example, following controlled cortical impact (CCI)-
induced TBI, mRNA and protein levels of GLT-1 were reduced in
the rat frontal cortex at 24 and 72 h following the injury.19 In the
LFPI model, GLT-1 protein levels were decreased in the ipsilateral
cortex at 7 days post-injury.21 These findings prompted us to ex-
amine the effects of TBI on glutamate transporter expression and
activity following acute TBI. We used Western blot analysis, bio-
chemical fractionation, 3H-glutamate uptake assays, and kinome
array profiling to investigate glutamate transporter fidelity in a
well-characterized model of TBI.
Methods
Animals
Adult male Sprague–Dawley rats (348 – 40 g, age 8–9 weeks, at
time of surgery; Charles River Laboratories International, Inc.)
were housed two per cage on a 12 h light/dark cycle in a temper-
ature- (22C) and humidity-controlled facility and allowed stan-
dard rat chow and water ad libitum. All animal care and
experimental procedure complied with National Institutes of
Health (NIH) guidelines and were approved by the Institutional
Animal Care and Use Committee of the University of Alabama at
Birmingham. For generation of tissue, animals were divided into
two groups. Uninjured control animals received trepanation only
(Sham, n = 5), whereas the injured animals received TBI using an
LFPI model as described subsequently (TBI, n= 5). For selected
experimental procedures, tissue was also taken from uninjured,
non-surgery rats (Naı¨ve, n = 5). Five animals from each condition
were humanely euthanized at 24 h post-treatment, and tissue was
processed for isolation of membrane vesicles, electron microscopy
(EM), Western blot analysis, and kinome array analysis.
Surgical procedure
Surgical procedure was performed as previously described.22,23
Briefly, animals were anesthetized with 4% isoflurane gas in an O2
carrier for 4min, followed by intraperitoneal injection of 100/
10mg/kg mixture of ketamine/xylazine; anesthesia was maintained
via ventilation with 1.5–3% isoflurane gas for the duration of sur-
gery. Normothermia was maintained throughout surgery by keep-
ing the animals on a water-jacketed heating pad. After securing the
animal in a stereotaxic frame, a midline scalp incision was made
and the skin and fascia reflected to expose the bregma, lambda, and
sagittal sutures, as well as the lateral ridge. A 4.8mm craniectomy
was trepanned over the right parietal cortex, midway between
bregma and lambda, tangential to the sagittal suture. A rigid plastic
injury tube (modified female Luer-lock 20G needle hub) was
bonded to the skull with cyanoacrylate adhesive over the open
craniectomywith the dura intact, and a stabilizing screwwas placed
in a burr hole drilled rostral to bregma on the ipsilateral side. The
injury tube and stabilizing screw were secured with dental acrylic.
The scalp was then sutured and the animal was placed in a warmed
recovery cage.
Induction of LFPI
Experimental TBI was performed using a fluid percussive device
(VCU Biomedical Engineering, Richmond, VA) as previously
described.22,23 The device consists of a Plexiglas cylinder (60 cm in
length and 4.5 cm in diameter) filled with sterile water. A piston is
mounted on O-rings at one end and an extracranial pressure
transducer (Entran Devices, Inc.) 5mm tube (internal diameter
2.6mm) ending in a male Luer-lock is fitted at the other end. The
animal was anesthetized with 4% isoflurane gas for 4min, and TBI
(2 atm) was induced by rapidly injecting a small volume of sterile
saline into the closed cranial cavity over the right ipsilateral
hemisphere with the fluid percussion device. Immediately after the
impact, the animal was removed from the device, monitored for
duration of apnea and unconsciousness, and re-sutured while re-
ceiving supplemental oxygen ventilation. The magnitude of the
pressure pulse was measured by a pressure transducer, stored on an
oscilloscope, and later converted to atmospheres (atm). The pres-
sure pulse was monitored and controlled in order to deliver an
equivalent impact of 2.0 atm to each animal.
Brains were extracted and dissected as previously described,
with gross anatomical markers used to divide tissue into 20 separate
areas of interest, and immediately flash frozen on dry ice.24 Tissue
was kept at -80C until needed.
Isolation of membrane vesicles
The membrane vesicle isolation protocol was adapted from
previous studies utilizing human cortical tissue and optimized to
yield both neuronal and glial membrane elements.25 Frozen cortical
tissue (150–200mg) from the area of injury or the ipsilateral hip-
pocampus (HPC) was transferred to 5mL of ice-cold HEPES-
buffered sucrose solution (HBSS) at pH 7.4 in a glass homogenizer
(Kontes Glass Co, #21, Vineland, NJ) and dounced (15 strokes).
The homogenate was transferred to microcentrifuge tubes and spun
at 800g (3000 rpm) for 10min at 4C. The supernatant was trans-
ferred to new microcentrifuge tubes and spun at 10,000g for 15min
at 4C. The resulting pellet was resuspended in 2mL of HBSS and
layered onto 3mL of 1.2M sucrose in a swinging bucket rotor
(Beckman Coulter, SW60Ti, Pasadena, CA) and spun at 230,000g,
45min at 4C. The band above the sucrose gradient (supernatant)
was collected and placed in 1.5mL of either standard glutamate
uptake buffer (NaCl, 144mM; KCl, 2.5mM; CaCl2, 1.2mM;
MgCl2, 1.2mM; K2HPO4, 1.3mM; glucose, 10mM; HEPES,
10mM; and Tris, 5mM), or a sodium-free glutamate uptake buffer
with choline chloride (144mM) substituted for sodium chloride.
The supernatant was then pipetted onto a 2.5mL column of 0.8M
sucrose and spun at 230,000g, 45min at 4C. The pellet was col-
lected and suspended in 100 lL of glutamate uptake buffer with or
without sodium. Total protein concentration was determined for
each sample with a bicinchoninic acid (BCA) assay.
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[3H]-glutamate uptake
Sample tubes were prepared with 20lg of re-suspended syn-
aptosomes, and placed into tubes containing either standard glu-
tamate uptake buffer at 37C (37, n = 5), standard glutamate
uptake buffer at 0C (0, n = 5), Na+-free glutamate uptake buffer at
37C (Na+, n= 5), or standard glutamate uptake buffer with added
5M L-trans-pyrrolidine-2,4-dicarboxylic acid at 37C (PDC)
(n= 5). The tubes were then pre-incubated for 30min at their re-
spective temperatures. Following incubation, 10lM of unlabeled
glutamic acid and 2lCi of [H3]-glutamate (Perkin Elmer Inc.,
Walther, MA) were then added to the samples for 10min, with a
final volume of each tube reaching 500lL. The synaptosomal so-
lution was then filtered through a cell harvester (Brandel, Gai-
thersburg, MD) with 0.9% cold saline solution and trapped on
Whatman GF/C filters (GE Healthcare, Buckinghamshire, UK).
The filters were then collected into scintillation vials, suspended in
5mL of Ultima-Gold scintillation fluid (Perkin Elmer Inc.,
Waltham, MA) and counted on a scintillation counter (Beckman
Coulter, LS 6500, Pasadena, CA).
Western blot analysis
Ten micrograms of total protein in 17 uL sample buffer (In-
vitrogen, Carlsbad, CA) were loaded into a pre-cast sodium do-
decyl sulfate (SDS) gel with a 4–15% gradient (Mini-PROTEAN
TGX Bio-rad, Hercules, CA) and run at 180V for 1 h, then
transferred to polyvinylidene fluoride membranes (Bio-rad) at 16V
for 30min. Membranes were blocked overnight in blocking buffer
(Li-Cor, Lincoln, NE) and then incubated in primary antibodies
(Abs; guinea-pig anti-GLT-1, AB1783 Millipore, Billerica, MA,
dilution 1:5000; mouse anti-valosin-containing protein, AB11433
Abcam, Cambridge, MA, dilution 1:2500; rabbit anti-synaptophysin,
AB23745 Abcam, dilution 1:50000) overnight at 4C and then wa-
shed three times with tris-buffered saline (TBS). Near-infrared sec-
ondary antibodies were used at 1:5000, and blots were imaged on a
Li-Cor Odyssey Imager as previously described.26 We tested our
Western blot assays using varying concentrations of total protein of
rat brain tissue homogenate. These control studies demonstrated that
our assays were linear for the protein concentrations used in our
Western blot studies.
EM
Synaptosomal fragments were fixed in 1/2 Karnovsky fixative
(2.5% paraformaldehyde and 2.0% glutaraldehyde in 0.1M Caco-
dylate buffer) and then post- fixed in 1% osmium tetroxide in 0.1M
Caco buffer. Samples were then dehydrated in a graded series of
ethanol, and infiltrated and embedded in Embed 812 resin. Fol-
lowing embedding, ultrathin sections were collected on copper
mesh grids, post-stained with uranyl acetate and lead citrate, and
examined using an FEI Tecnai T-12 electron microscope. All im-
aging was performed at the University of Alabama at Birmingham
Electron Microscopy Core (Birmingham, AL).
Statistical analysis
All statistical tests were done with Prism version 6 (GraphPad
Software Inc.). Data were tested for normality of distribution, and
differences between conditions were assessed using one way
analysis of variance (ANOVA) or t test, as appropriate. Post-hoc
analysis was performed with Tukey’s multiple comparison test
when necessary. For all tests a= 0.05. All data are reported as mean
value – standard error of the mean (SEM).
Kinome array profiling
Profiling of serine-threonine kinome (STK) activity was per-
formed using the PamStation12 microarray (PamGene International)
and STK PamChips containing 144 consensus phosphopeptide se-
quences per well (4 of which are internal controls), immobilized on
porous ceramic membranes. Each PamChip well was blocked with
2% bovine serum albumin (BSA) before 2lg of protein in the
manufacturer’s kinase buffer (PamGene), 157lM adenosine tri-
phosphate (ATP), and FITC-labeled anti-phospho Ser/Thr antibodies
(PamGene) were added in each well. The homogenized samples
containing the active kinases and assay mix were pumped through
the wells to facilitate interaction between kinases in the sample and
specific peptide substrates immobilized on the chip. The degree of
phosphorylation per well was measured in real time using Evolve
(PamGene) kinetic image capture software. The software captures
FITC-labeled anti-phospho antibodies binding to each phosphory-
lated peptide substrate every 6 sec for 90min.27 Primary analyses
were performed from integrated exposure times for each spot (10ms,
20ms, 50ms, 100ms, and 200ms) using steady state as quality
control. Integrated spot intensities with the 99th percentile were used
to calculate a minimal positive shift, and data were log2 transformed.
These log-transformed spot intensities are the ‘‘signal’’ for each
peptide. The signal intensities for each peptide were analyzed using
BioNavigator 5.2 Software (PamGene).27 Rodent brain samples
evaluated here using the array are comparable to previous data ac-
quired by us in human samples.28
A control array was run without the addition of ATP to identify
nonspecific binding of labeled antibody to the array substrate (data
not shown). Peptides with significant background signal in the -
ATP condition (higher than the +ATP condition) were excluded
from further analysis. Four peptide probes were excluded based on
these criteria. Peptide probes for which signal was not detected in
the +ATP condition were also excluded from analyses. Three ad-
ditional peptides were excluded under this criterion, leaving a total
of 133 peptide substrates.
Signal intensity data for each peptide (excluding the four control
peptide substrates, three peptide substrates for whom kinase ac-
tivity could not be detected, and four peptides with nonspecific
activity) for all rodent samples was tested for outliers (– 2.5 SD
from the mean), which were eliminated from our analyses. Com-
parisons for each peptide substrate were made using the mean
values for each substrate for LFPI (n= 5) and Sham (n = 5) animals.
The ratio of the means was used to calculate fold change for each
peptide. Peptides with a fold change –1.15 were considered sig-
nificant for further analysis.
Identification of upstream kinases
Using Kinexus Phosphonet (Kinexus Bioinformatics) and GPS
2.1 prediction algorithms, we identified protein kinases acting
on phosphorylation sites within the array peptide sequences.29,30
These programs provide ranked predictions for serine-threonine
kinases targeting putative phosphorylation sites in the peptide se-
quence. The top three kinases predicted by Kinexus and kinases
with scores more than twice the prediction threshold for each
phosphorylation site were included as predicted kinase ‘‘hits’’ for
TBI-altered substrates. We then calculated the frequency of each
kinase for the cortical and hippocampal data sets.
Random sampling analyses
To determine which upstream kinases are most likely to be
important in the signaling network in acute TBI based on our ki-
nome array data, we performed a random sampling analysis.31,32
We generated data sets (n = 2000) where each data point includes
randomly selected reporter peptide substrates from the kinome
array. Each data point in the analyses of frontal cortex included 25
substrates, matching the number of substrates with LFP-induced
changes in kinase activity in the cortex. Each data point in the
analysis of the HPC included 19 substrates, matching the number of
substrates with LFP-induced changes in kinase activity in HPC.
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Using Kinexus PhosphoNet and GPS 2.1 prediction algorithms, we
identified kinases predicted to target each phosphorylation site on
every array substrate, and then calculated the frequency of each
kinase for all 2000 data points in cortical and hippocampal data
sets. From these data we generated an ‘‘expected’’ distribution for
each protein kinase. Means and standard deviations were calculated
for each expected distribution. Kinases in the LFP data points with
observed frequencies falling outside two standard deviations from
the expected mean (derived from randomly generated data points)
were carried forward into our network analyses.
Signaling network modeling
Kinases implicated by the random sampling analyses were used
to create a model TBI signaling network. We generated a network
model that 1) represents the number of direct interactions between
protein kinase ‘‘hits’’ identified from our random sampling analy-
ses, and 2) also represents other protein kinases in the Ingenuity
Pathway database that have direct interactions with the these pro-
tein kinase ‘‘hits.’’33 For the second group, we restricted the In-
genuity Pathway Analysis (IPA) grow tool to ‘‘kinases’’ and
‘‘direct interactions’’ and used the connect tool to create a kinase
network.33 The resulting output was refined by removing kinases
with fewer than two connections to the emerging network. Because
signaling networks may be amplified or muted based on the number
of interactions between kinases, we weighted our model based on
the number of interactions found for each kinase in the network.
IPA
The resulting TBI kinase network was further analyzed using
IPA, as previously described, for associated upstream regulating
factors and physiological functions.28
Exploratory kinome array studies.
For the inhibitor studies, 10 ug protein from each of the LFPI
(n = 5) and Sham (n= 5) rodents were pooled to make a single
FIG. 1. Righting time following 2.0 atm lateral fluid percussion injury (LFPI) or sham surgery in adult male rats (A). Electron
micrograph of membrane vesicles isolated using density centrifugation from the prefrontal cortex (B) and expression of synaptophysin
(Syn) protein in membrane vesicles from naı¨ve, sham surgery, and LFPI rodents 24 h after injury (C and D). Data were normalized to
valosin-containing protein (VCP) and expressed as mean –SEM. n = 5 per group, *p< 0.05.
FIG. 2. 3H-glutamate uptake in membrane vesicles isolated from adult rats 24 h after lateral fluid percussion injury (LFPI) or sham
surgery. Low temperature (0C), absence of sodium (Na+), and the excitatory amino acid transporter inhibitor L-trans-pyrrolidine-2,4-
dicarboxylate (PDC) all inhibited uptake compared with the 37C positive control (A). 3H-glutamate uptake in membrane vesicles
isolated from the prefrontal cortex (B) and hippocampus (C) 24 h following LFPI or sham. Data expressed as mean counts per minute –
SEM. n = 5 per group, *p< 0.05.
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pooled TBI sample and a single pooled Sham sample. Each sample
was evaluated with the kinome array as previously described in
the presence and absence of specific inhibitors for protein kinase B
(Akt; Calbiochem 124005), c-Jun N-terminal kinase ( JNK;
SP600125, Calbiochem), and mitogen-activated protein kinase
kinase (MEK; D-erythro-sphingosine N-hexanoyl, Calbiochem)
plus protein kinase C (PKC; Bisindoylmaleimide Hydrochloride,
Cell Signaling) at a final concentration of 150 uM.28 PKC andMEK
were combined because of limited space on the array plate (and we
chose to prioritize Akt and JNK in this study for theoretical rea-
sons). The ratio of kinase activity in the inhibitor/no inhibitor
samples for each peptide substrate was used to calculate fold
change data. Difference in fold change was calculated as follows:
[(LFPI with inhibitor)/ (LFPI without inhibitor)] –[(Sham with
inhibitor)/(Sham without inhibitor)]. Only protein substrates from
the kinome array with detectable signal in Sham and LFPI samples
were included in the inhibitor study analyses.
Results
Rats that received LFPI exhibited a significantly longer duration
of latency for return of the righting reflex, a measurement of
transient unconsciousness, than did their sham-operated counter-
parts (t[8] = 5.096, p< 0.05) (Fig. 1A). This indicates that TBI-
induced loss of consciousness above and beyond that induced by
anesthesia alone. Additionally, the duration of unconsciousness is
similar to that observed with moderate TBI in this model.22 We
next confirmed the ultrastructural contents of our biochemical
fractionation protocol. Membrane vesicles isolated using density
centrifugation were imaged using EM (Fig. 1B). We found circular
membranous structures with areas of pre- and post-synaptic density
joining (black arrows). Expression levels of the synaptic marker
synaptophysin did not significantly differ between experimental
conditions (F[2,11]= 0.439, p= 0.66) (Fig. 1C and D).
We next evaluated glutamate uptake in membrane vesicles
isolated from rats 24 h after LFPI. 3H-glutamate uptake was
temperature and sodium dependent, and was diminished by the
excitatory amino acid transporter inhibitor L-trans-pyrrolidine-2,
4-dicarboxylate (PDC) (F(3,16)= 10.90, p< 0.05) (Fig. 2A). 3H-
glutamate uptake was lower (39%) in membrane vesicles isolated
from the injured cortical hemisphere of LFPI rats than in sham
surgery controls (t[8] = 3.43, p < 0.05) (Fig. 2B). We detected no
differences in 3H-glutamate uptake in membrane vesicles isolated
from the HPC (Fig. 2C). To determine if changes in 3H-glutamate
uptake in the cortex were secondary to decreased GLT-1 expression
versus other mechanisms, we measured GLT-1 protein levels using
Western blot analysis. We did not detect any changes in total
(monomer and dimer) GLT-1 protein levels in the prefrontal cortex
or HPC in brain homogenate (Fig. 3A and B) or membrane vesicles
(data not shown).
Since glutamate transport activity is potently regulated by pro-
tein kinases, we used a kinome array platform to explore global
changes in kinase activity in LFPI. In the prefrontal cortex, 17
peptide substrates had increased phosphorylation levels ‡1.15-fold
24 h after LFPI compared controls, whereas eight peptides were
‡1.15-fold (Table 1). In the HPC, three peptide substrates were
increased ‡1.15-fold, whereas 16 peptides were decreased ‡1.15-
fold following TBI (Table 2).
Using publicly available databases, we mapped protein kinases
specific for the peptide substrates from the kinome array, and
performed permutation analyses to identify kinases across the re-
porter peptide data set with a high probability of being true posi-
tives (Table 3). We randomly generated a data set for each kinase
(n = 2000) in which each data point reflected peptide substrates
randomly selected from the kinome array. For the prefrontal cortex,
we randomly selected 25 substrates for each data point, and for the
HPC we randomly selected 19. We then made a frequency plot of
the number of times a mapped kinase appeared in each randomly
generated sample (Fig. 4, open bars). To be considered a true
positive and carried forward into our network model, a kinase had
to have an experimentally determined mapping frequency more
FIG. 3. Expression of excitatory amino acid transporter 2
(glutamate transporter-1 [GLT-1]) protein in brain homogenate
from rats that had had lateral fluid percussion injury (LFPI) and
sham surgery 24 h after injury in the prefrontal cortex (A) and
hippocampus (B). Data were normalized to valosin-containing
protein (VCP) and expressed as mean – SEM. n = 5 per group.
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than two standard deviations from the mean of the randomly gen-
erated data set (Fig. 4, red lines). Nine protein kinases met this
threshold in the prefrontal cortex, whereas four met this threshold
in the HPC (Table 3).
We next used these high-yield kinases to construct signaling
network interaction models for the prefrontal cortex and the HPC.
We constructed a kinase interaction network model based on
known interactions between kinases identified from our 24 h post-
LFPI studies (Table 3) and the IPA database (gray circles and
darker lines). We also modeled the up- and downstream kinases
associated with our ‘‘hits’’ from Table 3 (white circles and lighter
lines). The size of the circles reflects a smaller or larger number of
interactions in the model. Kinases with the largest circles, including
Akt and p21-activated kinases (PAK) in the cortex (Fig. 5) and PKC
and protein kinase A (PKA) in the HPC (Fig. 6) are predicted to
have the most involvement in the lesion and may be provisionally
identified as signaling nodes in acute TBI.
We performed exploratory inhibitor studies in frontal cortex
using the kinome array platform to investigate the regulation of
several kinases implicated in TBI pathophysiology. To ensure that
we were investigating drug effects, we increased our fold change
threshold to –1.5. Using this standard, kinase activity was de-
creased on 13 substrates in the Sham sample and 6 substrates in the
LFPI sample, whereas activity increased on 6 substrates in the
Sham sample and 16 substrates in the LFPI sample in the presence
of the Akt inhibitor (Fig. 7A, left column). JNK inhibition de-
creased kinase activity on 20 substrates in the Sham sample and 4
substrates in the LFPI sample (Fig. 7A, center column). Kinase
activity increased on no Sham substrates and on nine LFPI sub-
strates in the presence of JNK inhibitor. Kinase activity was de-
creased on 41 and 46 substrates in the Sham and LFPI samples,
respectively, by the combination of PKC and MEK inhibitors
(Fig. 7A, right column). Kinase activity increased on 20 substrates
in the Sham sample and on 10 substrates in the LFPI sample in the
presence of the PKC-MEK inhibitor combination.
To investigate this further, we plotted the difference between the
(+) inhibitor and the (-) inhibitor values LFPI and Sham for each
reporter peptide (the change in fold change, Fig. 7B). Peptide
substrates with a change in fold change of >0.5 were deemed to be
differentially phosphorylated. Peptide substrates on the array that
were not differentially phosphorylated are plotted as gray circles
(-0.5 to 0.5). The Akt and JNK inhibitors yielded 41% and 29%
Table 1. Substrate Peptides Differentially Phosphorylated Between Lateral Fluid Percussion Injury
and Sham in Frontal Cortex on the Kinome Array
Increased signal UniProt accession Abbreviation Fold change Selected mapped kinases
B-2 adrenergic receptor P07550 ADRB2 1.16 MSK CAMK4 Akt CAMK2
Annexin1 P04083 ANXA1 1.22 PKG RSK Akt PKA
Cystic fibrosis transmembrane conductance regulator P13569 CFTR 1.21 CDK GRK PKD PKA
Choriogonadotropin subunit beta P01233 CGB 1.17 MSK PKG Akt GRK MEK
Colony-stimulating factor 1 receptor P07333 CSF1R 1.25 PIM PKG DMPK PAK
Phospholemman ion transport regulator O00168 FXYD1 1.22 PKA PKC CAMK2 MLK
G protein-coupled receptor 6 P46095 GPR6 1.26 GRK PKC PKG RSK
G protein signaling modulator P81274 GPSM2 1.31 PKA RSK CAMK1 CAMK2
Glycogen (starch) synthase, liver P54840 GYS2 1.20 PKA CASK RSK Akt
Potassium voltage-gated channel A1 Q09470 KCNA1 1.29 PKA ERK RSK CASK
Potassium voltage-gated channel A2 P16389 KCNA2 1.32 GRK RSK CAMK1 CASK
Potassium voltage-gated channel A3 P22001 KCNA3 1.32 GRK DMPK IKK MLK
Potassium voltage-gated channel B1 Q14721 KCNB1 1.17 DMPK GRK PKC PKG
Neutrophil cytosolic factor P14598 NCF 1.17 PIM PKC MSK PAK
Phosphorylase kinase a1 P46020 PhKA1 1.16 PIM PKA SGK Akt
Protein tyrosine kinase 6 Q13882 PTK6 1.18 PAK GRK MAP2K PKD
v-raf viral oncogene P04049 RAF1 1.23 AKT DMPK PKA PKC
v-rel viral oncogene Q04864 REL 1.23 PIM PKG PKA DMPK
Decreased signal UniProt accession Abbreviation Fold change Selected mapped kinases
Branched chain ketoacid
Dehydrogenase kinase
O14874 BCKDK -1.19 SGK PRKX skMLCK RSK
ETS domain-containing protein Elk-1 P19419 ELK1 -1.34 GRK PKC PhK CDK
Kainate receptor 1 P39086 GRIK1 -1.84 GRK MLK ANP RSK
Lamin A P02545 LMNA -1.17 LKB MLK MK2/3 PIM
M-phase phosphoprotein 6 Q99547 MPHOSPH6 -1.15 JNK p38 ERK CDK
Neurotrophic tyrosine
Kinase receptor 3
Q16288 NTRK3 -1.3 JNK CHEK1 CDK MLK
Retinoblastoma-like 2 Q08999 RBL2 -1.2 p38 JNK ERK CDK
MSK, mitogen- and stress-activated protein kinase; CAMK, calcium/calmodulin-dependent protein kinase; Akt, protein kinase B; PKG, protein kinase G;
RSK, ribosomal s6 kinase; PKA, protein kinase A; CDK, cyclin-dependent kinase; GRK, G protein-coupled receptor kinase; PKD, protein kinase D; MEK,
mitogen-activated protein kinase kinase; DMPK, dystrophia myotonica protein kinase; PAK, p21-activated kinase; PKC, protein kinase C; MLK, mixed
lineage kinase; CASK, calcium/calmodulin-dependent serine protein kinase; ERK, extracellular signal-regulated kinase; IKK, I kappa B kinase; SGK, serum/
glucocorticoid regulated kinase; MAP2K, mitogen-activated protein kinase kinase; PRKX, protein kinase X-linked; skMLCK, skeletal muscle myosin light
chain kinase; PhK, phosphorylase kinase; ANP, atrial natriuretic peptide; LKB, liver kinase B; MK2/3, MAPK-activated protein kinases 2 and 3; JNK, c-Jun
N-terminal kinase; p38, p38 mitogen-activated protein kinase; CHEK1, checkpoint kinase 1; ETS, E26 transformation-specific.
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differentially phosphorylated substrates, respectively. The vast
majority of these, 93% and 88%, were substrates for which changes
in activity were in the opposite directions (solid black circles) be-
tween LFPI and SHAM samples. With combined PKC-MEK in-
hibition, 49% of substrates were differentially phosphorylated,
however the majority of these (61%) represent differences in
magnitude of fold change in the same direction (open circles).
Panels C and D are representative kinetic curves of selected kinases
from the array with and without inhibitor (Fig. 7).
Finally, we performed IPA analyses on the kinases included in
the models for the cortex (Fig. 5) and HPC (Fig. 6). Kinases
identified in the cortex were primarily associated with cell death
and apoptosis pathways, whereas in the HPC, kinases were asso-
ciated with apoptosis, proliferation, cytoskeletal remodeling, and
cell cycle progression (Table 4).
Discussion
The results from these experiments point to a deficit in the
function of glutamate transporters following TBI that is indepen-
dent of changes in protein concentration, and may be mediated by
aberrant activity of signaling pathways. Western blot analysis
demonstrated no differences in GLT-1 protein expression in either
cortical or hippocampal homogenates (Fig. 3A and B) 24 h fol-
lowing experimentally induced (2.0 atm) LFPI. However, mem-
brane vesicles isolated from rats 24 h after brain injury exhibited
decreased 3H-glutamate uptake in the cortex, indicating diminished
capacity to effectively remove glutamate from the extracellular
space (Fig. 2B). Because we did not find changes in total GLT-1
protein levels, these results suggest a mechanism other than pro-
teolysis, and/or decreased de novo expression. As kinases and other
signaling molecules are potent regulators of glutamate transporters,
we investigated the role of kinase activity on transporter function.
Results from the kinome array studies indicate that multiple kinase
signaling pathways are altered 24 h after LFPI. Our data yielded a
TBI-associated signaling network that included nodes for Akt,
PKC, and mechanistic target of rapamycin (mTOR) kinases. Be-
cause many of these kinase pathways are known regulators of
GLT-1 function in uninjured tissue, we postulate that changes in
signaling networks account for the diminished uptake capacity we
observed in the cortex in acute TBI.34–37
The results of our experiments point to a deficit in glutamate
reuptake without a concomitant reduction in transporter expression
in either the cortex (Fig. 3A) or HPC (Fig. 3B). Multiple studies
demonstrate altered expression of glutamate transporters following
TBI; however, these effects vary based on the animal model used to
induce the injury.38 CCI models of injury consistently demonstrate
downregulation of cortical and hippocampal expression of GLT-1,
as well as decreases in mRNA levels for the transporter beginning
4–6 h after injury, and persisting for up to 72 h.9,19,39 However,
studies using LFPI have found mixed effects on glutamate trans-
porter expression levels. Whereas there are reports of decreased
(29%) GLT-1 expression in the ipsilateral cortex at 7 days post-
injury,21 other studies detected no changes in cortical expression of
the transporter up to 24 h post-injury, and found increases in hip-
pocampal GLT-1 expression across the same time period.40 The
discrepancies between these models may be a result of differences
in injury location, mode or severity of the injury, the focal nature of
Table 2. Substrate Peptides Differentially Phosphorylated Between Lateral Fluid Percussion Injury
and Sham in the Hippocampus on the Kinome Array
Increased signal UniProt accession Abbreviation Fold change Selected mapped kinases
B-2 adrenergic receptor P07550 ADRB2 1.17 MSK CAMK4 Akt CAMK2
Branched chain ketoacid
Dehydrogenase kinase
O14874 BCKDK 1.2 SGK PRKX skMLCK RSK
Serine/threonine-protein kinase
Chk2
O96017 CHEK2 1.17 TBK1 IKK PIM PLK
Cyclic AMP-responsive element-
binding protein 1
P16220 CREB1 1.16 PKA PKC RSK CAMK1
ETS domain-containing protein
Elk-1
P19419 ELK1 1.15 PKA PKC RSK CAMK1
Kainate receptor 1 P39086 GRIK1 2.23 GRK MLK ANP RSK
Potassium voltage-gated channel
subfamily A member 6
P17658 KCNA6 1.19 Akt DMPK PKA PDK
Phosphorylase kinase a1 P46020 PHKA1 1.19 PIM PKA SGK Akt
Cardiac phospholamban P26678 PLN 1.17 RSK PKC GRK DMPK
Decreased signal Uniprot accession Abbreviation Fold change Selected mapped kinases
Potassium voltage-gated channel B1 Q14721 KCNB1 -1.22 DMPK GRK PKC PKG
Kinesin family 2C Q99661 KIF2C -1.17 PKC PAK GRK PKD
Protein kinase C beta type P05771 PRKCC -1.18 PKA PKC KIS RSK
v-raf viral oncogene P04049 RAF1 -1.17 Akt DMPK PKA PKC
v-rel viral oncogene Q04864 REL -1.21 PIM PKG PKA DMPK
v-src sarcoma P12931 SRC -1.15 GRK MLK HCK BLK
MSK, mitogen- and stress-activated protein kinase; CAMK, calcium/calmodulin-dependent protein kinase; Akt, protein kinase B; PKG, protein kinase
G; RSK, ribosomal s6 kinase; PKA, protein kinase A; GRK, G protein-coupled receptor kinase; PKD, protein kinase D; DMPK, dystrophia myotonica
protein kinase; PAK, p21-activated kinase; PKC, protein kinase C; MLK, mixed lineage kinase; IKK, I kappa B kinase; SGK, serum/glucocorticoid
regulated kinase; PRKX, protein kinase X-linked; skMLCK, skeletal muscle myosin light chain kinase; ANP, atrial natriuretic peptide; TBK, TANK-
binding kinase; PLK, polo-like kinase; PDK, phosphoinositide-dependent kinase; KIS, kinase Interacting with stathmin; HCK, hematopoietic cell kinase;
BLK, B lymphocyte kinase; ETS, E26 transformation-specific.
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the CCI model, the recruitment of different second messenger
signals, or a combination of these factors.3,8 Studies in astrocyte
cultures found that the half-life of GLT-1 is >24 h41; therefore the
observed decreases in protein expression in the hours immediately
following CCI39 cannot be accounted for solely by diminished de
novo expression of the transporter.
A possible explanation for the reduction in transporter activity
following TBI involves the activity of caspase-3.42 Caspase-3
cleaves GLT-1 at aspartate 505, a highly conserved cytosolic C-
terminal site present on mouse, rodent, and human isoforms of the
transporter.10 Caspase-3 levels are increased in mammalian models
of TBI.43 Cleavage of GLT-1 by caspase-3 is dependent on
caspase-3 concentration and results in a significant loss of function
of the transporter; however, based on the epitope for our GLT-1
antibody, the truncated form is detectible on immunoblots, and we
did not detect a band at this predicted relative migration distance in
our Western blot studies.10 This finding prompted us to evaluate
changes in glutamate uptake in membrane vesicles and to explore
other mechanisms that may alter GLT-1 activity.
To our knowledge, only one other study has previously charac-
terized changes in glutamate uptake in a membrane preparation fol-
lowing experimental TBI.44 This study found decreased glutamate
uptake into synaptosomal membranes in the frontal cortex and HPC
in the CCI model that persisted for at least 24 h after injury.44 These
deficits were detected in comparison to the contralateral hemisphere
of the injured animals.44 Although these findings are consistent with
the changes we found in the frontal cortex, this prior study did not
examine GLT-1 protein levels, leaving the question of whether the
decrease in uptakewas secondary to a decrease inGLT-1 expression.
One possible explanation for the deficit in glutamate uptake
capacity is alterations in signaling networks following TBI. The
current study is limited somewhat by a lack of available reagents.
Specific phospho-GLT-1 antibodies are not available, and we are
not able to directly assess phosphorylation status of GLT-1. Nor are
we able to directly assess kinase activity on GLT-1 as a target
substrate, because GLT-1 is not present on the array. However,
GLT-1 expression can be upregulated through activation of Akt and
extracellular signal-regulated kinase (ERK) signaling pathways,
likely downstream of receptor tyrosine kinase (RTK) activation.45–49
GLT-1 expression and function is also modulated by PKC.50–53
Activation of PKC signaling rapidly decreases cell-surface ex-
pression of GLT-1 without decreasing total cellular GLT-1 protein
levels, whereas activation of PKA modulates transporter func-
tion.52–55 Therefore, alterations in the balance of signaling
Table 3. Predicted Kinases in Frontal Cortex and Hippocampus After Lateral Fluid Percussion Injury
Frontal cortex
Kinase Observed hits Distribution dean Standard deviation (SD) Z score Confidence interval
Confidence interval ‡2 SD
CAMK4 7 2.56 1.36 3.26 -0.16–5.28
CAMK2 14 8.25 2.08 2.77 4.09–12.41
GRK 15 9.26 2.16 2.66 4.94–13.58
PAK 9 4.66 1.77 2.45 1.12–8.21
Akt 10 5.68 1.91 2.27 1.86–9.49
PKD 5 2.18 1.30 2.18 -0.41–4.77
CK 8 4.35 1.72 2.13 0.91–7.78
DMPK 11 6.79 2.01 2.10 2.77–10.80
NEK 3 1.10 0.93 2.05 -0.75–2.95
Confidence interval between 1.5 and 2.0 SD
mTOR 4 7.76 2.05 1.83 3.66–11.85
DAPK 2 5.15 1.86 1.69 1.42–8.88
PKA 13 9.51 2.14 1.63 5.22–13.79
PKG 10 6.80 2.01 1.59 2.78–10.82
Hippocampus
Kinase Observed hits Distribution mean Standard deviation Z score Confidence interval
Confidence interval ‡2 SD
DMPK 8 4.07 1.63 2.41 0.80–7.33
PKA 10 5.70 1.80 2.40 2.11–9.29
mTOR 1 4.70 1.73 2.14 1.25–8.16
PKC 10 6.34 1.79 2.04 2.76–9.92
Confidence interval between 1.5 and 2.0 SD
GRK 9 5.56 1.76 1.96 2.03–9.08
CK 0 2.65 1.37 1.94 -0.09–5.39
CAMK2 8 4.95 1.72 1.78 1.51–8.38
PKD 3 1.26 1.02 1.70 -0.79–3.31
PRXX 3 1.35 1.05 1.57 -0.76–3.45
CDK 5 7.86 1.84 1.55 4.17–11.24
CAMK, calcium/calmodulin-dependent protein kinase; GRK, G-protein coupled receptor kinase; PAK, p21-activated kinase; Akt, protein kinase B;
PKD, protein kinase D; CK, casein kinase; DMPK, dystrophia myotonica-protein kinase; NEK, never in mitosis gene A-related kinase; mTOR,
mechanistic target of rapamycin; DAPK, death-associated protein kinase; PKA, protein kinase A; PKG, protein kinase G; PKC, protein kinase C; PRKX,
protein kinase, X-linked; CDK, cyclin-dependent kinase.
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molecules regulating transporter expression and/or function may
represent a potent mechanism for glutamate transporter dysfunc-
tion after TBI. Supporting this hypothesis, we found changes in
kinase activity for peptide substrates targeted by several serine/
threonine kinases. Our bioinformatic analyses yielded a signaling
network model that includes several kinases previously implicated
in rodent models of TBI, including Ca2+/calmodulin-dependent
protein kinase (CAMK)4, CAMK2, PAK, Akt, protein kinase D
(PKD), casein kinase (CK), PKA, mTOR, and PKC. The only ki-
nase common to both regions examined (at the highest threshold)
was dystrophia myotonica protein kinase (DMPK) (Table 3). Three
kinases (G protein-coupled receptor kinase [GRK], DMPK, and
never in mitosis gene A-related kinase [NEK]) from our network
model were not previously implicated in TBI. Given that we did not
find changes in glutamate uptake in the HPC, it is not surprising that
kinase network modeling yielded different kinase nodes with a
more extensive imputed network in the frontal cortex, where we
found a decrease in glutamate uptake.
The kinase with the most interactions in our frontal cortex sig-
naling model was Akt. Several studies have previously investigated
FIG. 4. Distribution plots of selected kinases for the cortex (A–D) and hippocampus (E–H) from permutation analyses of upstream kinases
identified by kinome array 24 h following lateral fluid percussion injury (LFPI). Data represent the frequency of kinases mapped to substrates
from the PamGene kinome array with –1.15-fold difference in activity in the LFPI group compared with the Sham group. The open columns
represent the randomprobability plot for the frequency of a selected upstreamkinase (n= 2000). Dashed lines indicate the number of times the
kinase actually appears in the cortex or hippocampus kinome data set. Gray area indicates –2 SDs from the mean of the probability plot.
CAMK2, calcium/calmodulin-dependent protein kinase type 2; Akt, protein kinase B; PKC, protein kinase C; PKA, protein kinase A.
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the role of Akt in TBI. Changes in phospho-AKT (pAKT) protein
levels were decreased, increased, or unchanged in areas outside of
the injury site (HPC and cortex) 1–72 h post-injury.34,36,37,56–60
Similarly divergent results were found at or near the injury
site;34,36,37,56–60 these disparate findings are likely the result of
differences in TBI models, in assays for pAKT, and in cellular
and subcellular expression patterns of AKT. For example, one
study found decreased pAKT levels in the cytoplasm, but in-
creases in the nucleus, with colocalization of pAKT and NeuN,
suggesting these changes are primarily associated with neurons.59
In addition, AKT is expressed and is active in astroglia, and
differences in cell-specific expression could account for the
variability in these reports, as there may be opposite changes in
astrocytes versus neurons that reflect proximity to the injury as
well as cell-specific pathophysiology. On balance, it appears that
decreased pAKT expression may be a plausible mechanism for
diminished GLT-1 activity in regions not directly injured. Inter-
estingly, treatment with progesterone increased pAKT, providing
a putative mechanism for restoring GLT-1 function.61 Finally,
there are several isoforms of Akt kinase, and the antibodies used
for many of these studies do not differentiate between Akt1, Akt2,
or Akt3.62
The kinase with the most interactions in our hippocampal sig-
naling model was PKC; this kinase was also an indirect factor with
a large number of interactions in our frontal cortex model. Several
studies have investigated the role of PKC following TBI. No
changes in PKC activity were detected 5–20min after initiation of
LFPI, but there was a shift in cytosolic to membrane-bound PKC a
and b in the cortex, with a decrease only in the cytosolic fraction in
the HPC.63 A different study found increased PKC activity 1 h post-
injury, with much higher increased PKC activity 3 h post-injury in
the dorsal HPC, a region somewhat removed from the midline
injury site.35 An increase in membrane bound PKC was also
FIG. 5. For the frontal cortex kinome array data, kinases implicated
by the random sampling analyses in Table 3 (gray circles) were
combined with upstream kinases (white circles) to create a kinase
network model. Using Ingenuity, kinases directly acting on our ki-
nases of interest (thicker lines) were added to the network. Finally,
Ingenuitywas used to identify known interactions among allmembers
of the network (thinner lines).Circle size corresponds to the number of
interactions (larger circles have more interactions). PAK, p21-
activated kinases; PKD, protein kinase D; GRK, G-protein coupled
receptor kinase; DMPK, dystrophia myotonica-protein kinase; CK,
casein kinase; NEK, never in mitosis gene A-related kinase; PKC,
protein kinase C; Akt, protein kinase B; CDK, cyclin-dependent ki-
nase; p38, p38 mitogen-activated protein kinase; CAMK2, calcium/
calmodulin-dependent protein kinase type 2; CAMK4, calcium/
calmodulin-dependent protein kinase type 4; MEK, mitogen-
activated protein kinase kinase; ERK, extracellular signal-regulated
kinase; GIT1, GPCR kinase-interacting protein 1; SRC, proto-
oncogene tyrosine-protein kinase SRC; TBK, TANK-binding kinase;
EGFR, epidermal growth factor receptor; IKK, I kappa B kinase;
SYK, spleen tyrosine kinase; STK, serine/threonine kinase; PRKDC,
DNA-dependent protein kinase; SRPK1, serine and arginine rich
splicing factor (SRSF) protein kinase 1; LYN, tyrosine-protein kinase
Lyn; FGFR, fibroblast growth factor receptors; PI3K, phosphoinosi-
tide 3-kinase; RSK, ribosomal s6 kinase; CAMK2K, calcium/
calmodulin-dependent protein kinase kinase 2.
FIG. 6. For the hippocampus kinome array data, kinases im-
plicated by the random sampling analyses in Table 3 (gray circles)
were combined with upstream kinases (white circles) to create a
kinase network model. Using Ingenuity, kinases directly acting on
our kinases of interest (thicker lines) were added to the network.
Finally, Ingenuity was used to identify known interactions among
all members of the network (thinner lines). Circle size corresponds
to the number of interactions (larger circles have more interac-
tions). DMPK, dystrophia myotonica-protein kinase; PKA, protein
kinase A; PKC, protein kinase C; PI3K, phosphoinositide 3-
kinase; PDK1, phosphoinositide-dependent kinase 1; SRC, proto-
oncogene tyrosine-protein kinase SRC; RAF1, rapidly accelerated
fibrosarcoma; SYK, spleen tyrosine kinase; TBK1, TANK-
binding kinase 1; GSK3, glycogen synthase kinase 3; ERK, ex-
tracellular signal-regulated kinase; PRKDC; DNA-dependent
protein kinase; STK, serine/threonine kinase; RSK, ribosomal s6
kinase; CK, casein kinase; EGFR, epidermal growth factor re-
ceptor; TK1, thymidine kinase 1; CHUK, conserved helix-loop-
helix ubiquitous kinase; ABL1, tyrosine-protein kinase ABL1;
mTOR, mechanistic target of rapamycin; AMPK, 5’ adenosine
monophosphate-activated protein kinase.
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FIG. 7. Serine/threonine PamGene kinome array analysis of acute (24 h) pooled sham (Sham, n = 5) and lateral fluid percussion injury
(LFPI, n= 5) cortical samples run in the presence and absence of specific inhibitors (i) for protein kinase B (Akt), c-Jun N-terminal kinase
( JNK),mitogen-activated protein kinase kinase (MEK), and protein kinase C (PKC). (A)Heatmap data is the ratio of the signal intensity of
the sample with inhibitor:sample without inhibitor for pooled Sham or pooled LFPI samples. Lighter to darker blue indicates decreased
phosphorylation (inhibition) of a specific array peptide, whereas lighter to darker red indicates increased phosphorylation (activation). (B)
Scatter plots of the change in fold change {[(LFPI w/inhibitor)/ (LFPI w/o inhibitor)] – [(Sham w/inhibitor)/(Sham w/o inhibitor)]} for
substrates from the kinome array with detectable signal in sham and LFPI samples. Substrates with a change in fold change >0.5 in the
opposite direction are represented with black circles; those with >0.5 fold change in the same direction are represented with white circles.
Gray circles indicate substrates with change in fold change <0.5 (regardless of valence). (C) and (D), representative activity curves for
select reporter peptides highlight the differential effects of inhibitors on kinase activity in Sham versus acute LFPI. (C) Estrogen receptor 1
(ESR1) signal – AKTi, (D) Calcium/calmodulin-dependent protein kinase 2 (KCC2G) signal – JNKi.
230
detected at 3 h, but no changes in activity were found 24 h after
LFPI in the HPC.35 A third study found increased expression of
PKC isoforms in the left prefrontal cortex 24 h following blast
exposure TBI, with an increase in PKCe and a decrease in PKCa
protein levels after treatment with the PKC modulator bryostatin-
1.64–66 These data were interpreted as indicating increased blood–
brain barrier permeability.64
Similar to Akt, the cellular specificity, subcellular localization,
and temporal changes in PKC localization and function will theo-
retically have a profound effect on GLT-1 function. The balance
between GLT-1 promoting and GLT-1 diminishing pathways fol-
lowing TBI is highlighted by astrocyte cell cultures examining the
effects of PKC. Long-term activation of PKC by phorbol esters in
cultured cortical astrocytes results in overall decreases in GLT-1
expression, similar to that exhibited in a number of animal models
of TBI.19,67 In contrast to long-term activation of PKC, shorter term
activity of the kinase results in sequestration of the transporter to an
intracellular storage site by a clathrin-mediated endocytotic
mechanism.67 This intracellular sequestration of GLT-1 diminishes
cell-surface expression, and thus would impact removal of gluta-
mate from the extracellular space, but does not lead to an overall
reduction in transporter expression. Our data are consistent with a
signaling milieu that diminishes GLT-1 activity in the frontal
cortex, but not HPC, 24 h after LFPI.
Several other kinases implicated in our signaling network were
previously implicated in TBI models. For example, PKA activity was
elevated in the medial prefrontal cortex (mPFC) following controlled
cortical impact 7 and 14 days post-injury, with no change in expres-
sion levels of the catalytic (C-a) or regulatory (RI-a/ß) subunits.68 In
the HPC 1h following lateral FPI, phospho-CAMKIV Thr196 and
phospho-CAMKI Thr177 were increased, whereas pCAMKII was
increased in membrane subcellular fractions from the parietal cortex
fractions at 30min, 4 h, and 24 h after injury.69 Changes in CAMKII
activity after TBI are particularly interesting, as the two isoforms of
GLT-1, GLT-1a, and GLT-1b are differentially regulated in vitro by
CAMKII.70 Increases in CAMKII activity suggested by increased
pCAMKII would destabilize GLT-1b membrane localization and
accelerate EAAT2b turnover, altering glutamate uptake dynamics and
neuronal activity.70 These findings are consistent with our signaling
network models, and suggest that regions outside of the direct injury
site may be differentially affected by LFPI.
We performed exploratory kinase inhibitor studies using pooled
samples from our 24 h LFPI experiments. In the frontal cortex,
inhibition of Akt or JNK had markedly divergent effects on phos-
phorylation of peptide substrates on the kinome array in LFPI
versus Sham animals. The kinome array readout is one that reflects
the net effects of kinase activity in a complex biological sample.
Inhibiting Akt and JNK activity in these complex samples led to
broad-based decreases in phosphorylation in the Sham animals, as
expected; surprisingly, a large number of peptide substrates had
increased phosphorylation in the LFPI samples. Two mechanisms
may explain these results. First, these kinases may be rendered
insensitive to inhibition in the aftermath of injury. Second, and
perhaps more likely, inhibition of these kinases facilitates nonse-
lective phosphorylation by other active kinases in a severely dys-
regulated signaling landscape. Serine-threonine kinases target
phosphorylation sites, in part, through the chemical properties of
flanking amino acid sequences, but will readily target suboptimal
sites when competition for those sites or additional specificity
factors are lacking.71 Overall, these results indicate that the sig-
naling milieu in the frontal cortex is profoundly altered, and that
regulatory mechanisms may be compromised acutely after TBI.
Table 4. Pathway Analyses: Predicted Regulating Factors with Kinases and Associated Functions
Name Abbrev. p value Kinases Function
Frontal cortex
Huntington protein HTT 7.20E-11 GRK; Akt; CK; CDK;
CAMKII; CAMKIV
Cell death; apoptosis; degeneration
Activating transcription factor 3 ATF3 1.62E-7 CDK; NEK Apoptosis; cell cycle progression
Retinoblastoma-like 1 RBL1 3.49E-7 CDK; NEK Cell cycle progression; cytostasis;
proliferation
Short stature homeobox SHOX 6.80E-7 CDK Cell cycle progression; apoptosis
Forkhead box M1 FOXM1 1.08E-6 CDK; NEK Proliferation; cell cycle progression
Tumor protein 53 TP53 1.10E-6 GRK; Akt; CAMKII;
CDK; PKD; PAK; NEK; CK
Apoptosis; cell cycle progression
Thyroid hormone receptor B THRB 1.13E-6 Akt; CDK Proliferation; abnormal morphology
Ubiquitin ligase E3A UBE3A 9.09E-6 CAMKII; CDK Capacitation; senescence;
Jun proto-oncogene JUN 1.47E-5 Akt; CDK; PAK Apoptosis; transformation; cell death
Hippocampus
Glucocorticoid receptor NR3C1 1.47E-6 PKA; PKC Apoptosis; remodeling
Tumor protein 53 TP53 1.43E-5 PKA; PKC Apoptosis; cell cycle progression
Sp1 transcription factor SP1 9.63E-5 PKA; PKC; DMPK Transcription; proliferation; cell death
Atrophin 1 ATN1 2.80E-4 PKA; PKC Apoptosis; cell death; differentiation
Huntington protein HTT 4.46E-4 mTOR; PKA; PKC Cell death; apoptosis; degeneration
Myogenic differentiation 1 MYOD1 6.30E-4 PKA Differentiation; cell cycle progression
ELAV-like family member 1 CELF1 9.63E-4 DMPK Degeneration
Muscleblind-like splicing regulator MBNL1 9.63E-5 DMPK Alternative splicing; abnormal morphology;
differentiation
Forkhead box D2 FOXD2 9.63E-6 PKA Proliferation; axon extension
Runt-related transcrition factor RUNX1 3.90E-3 PKC Differentiation; proliferation; apoptosis
GRK, G-protein coupled receptor kinase; Akt, protein kinase B; CK, casein kinase; CDK, cycli-dependent kinase; CAMK, calcium/calmodulin-
dependent protein kinase; NEK, never in mitosis gene A-related kinase; PKD, protein kinase D; PAK, p-21 activated kinase; PKA, protein kinase A;
PKC, protein kinase C; DMPK, dystrophia myotonica-protein kinase; mTOR, mechanistic target of rapamycin.
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Treatment with a combination of PKC and MEK inhibitors
primarily suppressed kinase activity, and the majority of differ-
entially phosphorylated substrates were changes in magnitude in
the same direction for the Sham versus LFPI groups. These
findings suggest PKC-ERK signaling may be relatively intact and
is consistent with our cortical signaling model, which directly
implicates Akt, but not ERK, PKC, or MEK, as a major signaling
node in TBI. Interestingly, pretreatment with a combination of
Akt and mTOR inhibitors improved post-injury wire grip per-
formance and hidden platform latencies, effects that may be
mediated by elevated glycogen synthase kinase 3 beta (GSK3b)
expression or activity in the HPC.36
There are several limitations to our study. All of our data were
generated from tissue samples from whole brain regions that were
blended. Because our samples included mixtures of all cell types
found in the brain, we cannot assess the relative contributions of
astroglia versus neurons, for example, when interpreting our data.
This is particularly relevant for studies of GLT-1, as most cortical
GLT-1 expression and activity is in astrocytes, whereas Akt is found
in both neurons and astroglia. Cell-level kinome studies are needed
to determine if the TBI signaling networks described in this study are
cell specific. Our model administers an FPI to the ipsilateral parietal
cortex; we examined the frontal cortex and HPC in our studies.
Therefore, our results may differ from other reports that directly
examined the injury site, and/or had more or less focal models, such
as CCI or blast injury, respectively. Additional studies are required to
determine whether GLT-1 expression is upregulated in neurons after
injury, which could provide an explanation for some of our current
findings. GLT-1 is primarily astrocytic with low GLT-1a expression
in a subset of neurons. Studies in other models of CNS injury
demonstrate phenotypic switching of typically ‘‘astrocytic’’ EAATs
onto neuronal processes.72Upregulated EAATexpression in neurons
could be a compensatory attempt by the brain to offset increases in
extracellular glutamate following TBI; however, these efforts may
ultimately harm neuronal tissue by making it more vulnerable to
excitotoxicity because of intracellular glutamate levels beyond the
buffering or metabolic capacity of neurons.73 It remains to be de-
termined whether GLT-1 function is regulated by direct interaction
with implicated kinases. Additional studies using kinase inhibitors in
synaptosomal preparations may help answer that question. Finally,
our GLT-1 antibody detects both GLT-1a and GLT-1b isoforms.
Future studies are required to determine the contributions of the two
isoforms to the observed deficits in cortical glutamate uptake.
We found differential changes in glutamate uptake and signaling
networks at sites removed from the direct injury site following LFPI.
This regional specificity suggests that the HPC and frontal cortex
may have different degrees and mechanisms of pathological re-
sponses, resilience, and/or sensitivity to injury. Building on this
work, future studies should examine cell-level changes in signaling
networks, with particular emphasis on astroglia versus neurons,
particularly in regions where most glutamate uptake is facilitated by
astroglia, such as the frontal cortex. Our data suggest that signaling
networks in the HPC supporting GLT-1 activity are not perturbed,
whereas the cortical signaling milieu is associated with diminished
glutamate uptake; drawing on the field of cancer biology to explore
the pharmacological effects of signaling network modulators may
provide new substrates to reverse the changes in the frontal cortex
and/or simulate the changes found in theHPC thatmay be protective.
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